Survivin、EGFR、Her2在乳腺癌中的表达水平及其相关性研究  

Study on expression and correlation of Survivin, EGFR and Her2 in breast cancer

作　　者：黄卓雅[1] 廖鹏娟 翁剑华[2] 刘英霞[3] 蔡敏仪 黄楚楚 钟鸣[3] 张旻 HUANG Zhuoya;LIAO Pengjuan;WENG Jianhua;LIU Yingxia;CAI Minyi;HUANG Chuchu;ZHONG Ming;ZHANG Min(Department of Pathology,Huizhou Central People's Hospital,Huizhou,Guangdong 516001,China;Department of Surgical Oncology,Huizhou First Hospital,Huizhou,Guangdong 516002,China;Department of Pathology,Huizhou First Hospital,Huizhou,Guangdong 516002,China;Department of Outpatient,Huizhou Central People's Hospital,Huizhou,Guangdong 516001,China)

机构地区：[1]惠州市中心人民医院病理科,广东惠州516001 [2]惠州市第一人民医院肿瘤外科,广东惠州516002 [3]惠州市第一人民医院病理科,广东惠州516002 [4]惠州市中心人民医院门诊部,广东惠州516001

出　　处：《热带医学杂志》2024年第6期867-871,F0002,共6页Journal of Tropical Medicine

基　　金：惠州市科技研发计划项目(2021WC0106454);惠州市科技计划项目(2020Y055)。

摘　　要：目的 检测存活素(Survivin)、表皮生长因子受体(EGFR)、人类表皮生长因子受体2(Her2)在乳腺癌组织中的表达水平,并探究三者表达的相关性及其与临床病理参数的关系。方法 收集2017年1月-2022年12月惠州市中心人民医院经病理确诊的76例女性乳腺癌患者的临床病理资料,包括年龄、绝经情况、病理分型、组织学分级、肿瘤淋巴结转移(TNM)分期、癌灶大小等。采用免疫组化法检测乳腺癌组织和癌旁组织中Survivin、EGFR、Her2表达水平;采用Spearman等级相关分析乳腺癌组织中Survivin、EGFR、Her2表达的相关性;χ^(2)检验分析Survivin、EGFR、Her2表达与乳腺癌临床病理参数的关系。结果 乳腺癌组织中Survivin、EGFR、Her2阳性表达率分别为59.21%、39.47%、52.63%,均高于癌旁组织的6.58%、9.21%、0.00%,差异均有统计学意义(χ^(2)=47.686、18.897、54.286,P均<0.05)。乳腺癌组织中Survivin与EGFR、Survivin与Her2、EGFR与Her2表达均成显著正相关(r=0.506、0.660、0.550,P均<0.05)。Survivin、EGFR、Her2在不同年龄、绝经情况、TNM分期患者癌组织中的表达差异均无统计学意义(χ^(2)=0.378、1.844、0.378;0.707、0.034、0.707;1.973、0.059、1.839,P均>0.05),Survivin、EGFR、Her2在不同病理分型、癌灶大小、组织学分级、淋巴结转移患者癌组织中的表达差异均有统计学意义(χ^(2)=34.200、27.306、31.901、24.945,12.944、15.797、7.165、21.170,15.271、35.496、25.451、36.067,P均<0.05)。结论乳腺癌组织中Survivin、EGFR、Her2表达明显升高,且三者之间成正相关;Survivin、EGFR、Her2在浸润性癌、癌灶>2 cm、组织学Ⅲ级、淋巴结转移阳性者中高表达。Objective To detect the expression levels of Survivin, epidermal growth factor receptor(EGFR), and human epidermal growth factor receptor 2(Her2) in breast cancer tissues, and explore the correlation between the expression of the three and its clinical pathological parameters. Methods The clinical and pathological data of 76 female breast cancer patients diagnosed pathologically at the Huizhou Central People's Hospital from January 2017 to December 2022 were collected, including age, menopausal status, pathological classification, histological grade, tumor node metastasis(TNM) stage, and size of cancer lesion etc. Immunohistochemistry was used to detect the expression levels of Survivin, EGFR and Her2 in breast cancer tissues and adjacent tissues;Spearman rank correlation was used to analyze the correlation of Survivin, EGFR and Her2 expression in breast cancer tissues;Chi-square test was used to analyze Survivin, EGFR and Her2 relationship between expression and clinicopathological parameters of breast cancer. Results The positive expression rates of Survivin, EGFR and Her2 in breast cancer tissue were 59.21%, 39.47% and 52.63%, respectively, which were higher than those in adjacent cancer tissues(6.58%, 9.21% and 0.00%), and the differences were statistically significant (χ^(2)=47.686, 18.897, 54.286;all P<0.05). The expressions of Survivin and EGFR, Survivin and Her2, and EGFR and Her2 in breast cancer tissues were significantly positively correlated(r=0.506,0.660,0.550;all P<0.05). There were no statistically significant differences in the expression of Survivin, EGFR and Her2 in cancer tissues of patients with different ages, menopausal status and TNM stages (χ^(2)=0.378, 1.844, 0.378;0.707, 0.034, 0.707;1.973, 0.059, 1.839;all P>0.05). The differences of Survivin, EGFR and Her2 expression levels in cancer tissues of patients with different pathological types,size of cancer lesion, histological grade and lymph node metastasis status were all statistically significant(χ^(2)=34.200, 27.306,31.901,24.945;12.

关 键 词：乳腺癌 存活素 表皮生长因子受体 人类表皮生长因子受体2 

分 类 号：R737.9[医药卫生—肿瘤]